'Patient disposition' presentation slideshows

Vital Signs The ultimate tradition An EBP Journey of discovery

Vital Signs The ultimate tradition An EBP Journey of discovery. Christine Malmgreen, RN-BC MS MA & Dr Lillie Shortridge-Baggett, EdD RN NP & Maggie Adler, RN-BC BSN Masters Candidate . Literature synthesis to establish an evidence-based policy on routine vital sign frequency.

2.18k views • 47 slides

PATIENT PREPARATION

PATIENT PREPARATION. CHAPTER 2 Part 1. PATIENT PREPARATION. The RVT has numerous responsibilities in the pre-anesthetic period. The pre-anesthetic period is the period immediately preceding the induction of anesthesia. This period can be from minutes to weeks .

599 views • 40 slides

Fibromyalgia: Creating a Claim

Fibromyalgia: Creating a Claim. James Witter MD, PhD Arthritis Advisory Committee June 23, 2003. Goals of Meeting. Gather input regarding development and approval for drugs that treat fibromyalgia Enrich analgesic guidance document Address an important public health issue

398 views • 28 slides

Slide 1

Slide 1. Presented By Maurice Perol at 2014 ASCO Annual Meeting. Conflict of Interest Disclosure. Presented By Maurice Perol at 2014 ASCO Annual Meeting. Limited Advancement in 2nd-Line Therapy. Presented By Maurice Perol at 2014 ASCO Annual Meeting. Ramucirumab and Angiogenesis.

419 views • 26 slides

Endodontics and the Dental Student

682 views • 24 slides

Presented By John Byrd at 2014 ASCO Annual Meeting

Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the Phase III <br />RESONATETM Trial. Presented By John Byrd at 2014 ASCO Annual Meeting. Background.

349 views • 18 slides

Infusional 5-FU/FA plus Oxaliplatin (FUFOX) vs. Capecitabine plus Oxaliplatin (CAPOX)

Tobias Arkenau. Infusional 5-FU/FA plus Oxaliplatin (FUFOX) vs. Capecitabine plus Oxaliplatin (CAPOX) as first-line treatment for metastatic colorectal cancer: safety and efficacy analysis from a phase III trial of the German AIO. Rationale for CAPOX in 1st-line ACRC.

301 views • 16 slides

Comparison of raltegravir vs efavirenz

289 views • 8 slides

Enrolled 95

Enrolled 95. Expansion cohorts*. Dose escalation cohorts. Allocated to BID schedule(n=26) Received OSI-906 (n=24 ). Allocated to BID schedule(n=31) Received OSI-906 (n=29 ). Allocated to QD schedule (n=38) Received OSI-906 (n=33).

147 views • 1 slides